| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $14,031 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Thompson Tommy G | director | 1 | $14,031 | 0 | $0 | $14,031 |
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17Ăź-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Over the last 12 months, insiders at TherapeuticsMD, Inc. have bought $14,031 and sold $0 worth of TherapeuticsMD, Inc. stock.
On average, over the past 5 years, insiders at TherapeuticsMD, Inc. have bought $7.01M and sold $12.95M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thompson Tommy G (director) — $14,031.
The last purchase of 8,400 shares for transaction amount of $14,031 was made by Thompson Tommy G (director) on 2025‑12‑23.
| 2025-12-23 | Thompson Tommy G | director | 8,400 0.0722% | $1.67 | $14,031 | +29.27% | ||
| 2025-04-14 | Walker Marlan D | Chief Executive Officer | 490 0.0047% | $1.00 | $489 | +34.95% | ||
| 2025-04-14 | Thompson Tommy G | director | 325 0.0031% | $1.00 | $326 | +34.95% | ||
| 2025-04-10 | Walker Marlan D | Chief Executive Officer | 1,167 0.0096% | $0.86 | $1,000 | +55.82% | ||
| 2025-04-09 | Walker Marlan D | Chief Executive Officer | 1,136 0.0095% | $0.87 | $994 | +49.44% | ||
| 2024-08-22 | Collins Cooper C. | director | 4,094 0.0352% | $1.73 | $7,099 | -33.14% | ||
| 2024-08-21 | Collins Cooper C. | director | 1,200 0.0105% | $1.70 | $2,039 | -30.77% | ||
| 2023-12-07 | Sale | Walker Marlan D | Chief Executive Officer | 4,550 0.0421% | $2.24 | $10,187 | -14.48% | |
| 2023-12-06 | Sale | Walker Marlan D | Chief Executive Officer | 14,500 0.1412% | $2.31 | $33,496 | -16.00% | |
| 2023-04-26 | Sale | Walker Marlan D | Chief Executive Officer | 692 0.0079% | $3.64 | $2,518 | -25.78% | |
| 2023-04-12 | Sale | Walker Marlan D | Chief Executive Officer | 1,170 0.013% | $3.65 | $4,276 | -23.14% | |
| 2023-01-27 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 49 0.0005% | $5.09 | $249 | -30.90% | |
| 2023-01-26 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,648 0.0183% | $5.08 | $8,371 | -27.36% | |
| 2023-01-24 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 7 <0.0001% | $5.31 | $37 | -29.39% | |
| 2023-01-23 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,302 0.0145% | $5.34 | $6,950 | -30.45% | |
| 2022-12-30 | Sale | Rubric Capital Management LP | director | 29,000 – | $1,333.00 | $38.66M | -31.75% | |
| 2022-12-09 | Sale | Bernick Brian | Co-Chief Executive Officer | 320 0.0035% | $6.31 | $2,020 | -39.64% | |
| 2022-12-09 | Rubric Capital Management LP | director | 14,825 0.1558% | $6.09 | $90,284 | -39.64% | ||
| 2022-12-08 | Rubric Capital Management LP | director | 300 0.0032% | $5.83 | $1,749 | -35.12% | ||
| 2022-12-07 | Sale | Naughton Gail K | director | 3,922 0.038% | $5.26 | $20,635 | -35.44% |
| Thompson Tommy G | director | 23179 0.2003% | $42,185.78 | 15 | 0 | +3.79% |
| Finizio Robert G | CEO | 17991637 155.4439% | $32.74M | 5 | 24 | <0.0001% |
| Milligan John C.K. IV | Secretary/CEO of subsidiary | 1752703 15.143% | $3.19M | 3 | 24 | <0.0001% |
| C.S. Finance LLC | 357606 3.0896% | $650,842.92 | 1 | 0 | ||
| JENSEN GERALD L | President | 258878 2.2367% | $471,157.96 | 26 | 0 | |
| SEGAL NICHOLAS | director | 215485 1.8617% | $392,182.70 | 1 | 1 | +111.31% |
| BISARO PAUL | director | 196864 1.7009% | $358,292.48 | 2 | 0 | +22.32% |
| Ling Karen | director | 130309 1.1258% | $237,162.38 | 1 | 0 | |
| DArecca James | Chief Financial Officer | 123830 1.0699% | $225,370.60 | 0 | 1 | |
| Russell Angus C. | director | 93500 0.8078% | $170,170.00 | 5 | 0 | <0.0001% |
| Walker Marlan D | Chief Executive Officer | 73639 0.6362% | $134,022.98 | 3 | 6 | +46.74% |
| BORKOWSKI EDWARD | EVP, Operations | 59248 0.5119% | $107,831.36 | 0 | 1 | |
| Collins Cooper C. | director | 52016 0.4494% | $94,669.12 | 9 | 1 | <0.0001% |
| Cartwright Daniel A | CFO | 40000 0.3456% | $72,800.00 | 0 | 4 | |
| Rosen David Efraim | 22000 0.1901% | $40,040.00 | 3 | 0 | <0.0001% | |
| MANDEL RICHARD H JR | director | 13100 0.1132% | $23,842.00 | 4 | 2 | |
| Donegan Michael C | Prin. Fin. and Acctg. Officer | 11853 0.1024% | $21,572.46 | 0 | 7 | |
| CARROLL J MARTIN | director | 10000 0.0864% | $18,200.00 | 1 | 0 | +16.97% |
| LaPenta Robert V Jr | director | 10000 0.0864% | $18,200.00 | 1 | 0 | +22.11% |
| MUSING JULES A. | director | 5000 0.0432% | $9,100.00 | 2 | 1 | +112.05% |
| Bernick Brian | Co-Chief Executive Officer | 3872 0.0335% | $7,047.04 | 2 | 24 | <0.0001% |
| Barlow Jane F | director | 3144 0.0272% | $5,722.08 | 1 | 0 | <0.0001% |
| Glickman Mark A | Co-Chief Executive Officer | 1294 0.0112% | $2,355.08 | 0 | 1 | |
| MASTROPIETRO DONALD R | 0 0% | $0 | 0 | 1 | ||
| JENSEN JULIAN D | director | 0 0% | $0 | 0 | 3 | |
| Naughton Gail K | director | 0 0% | $0 | 0 | 1 | |
| Tjon Robin Natalie | 0 0% | $0 | 0 | 1 | ||
| Jensen Development CO | Former President | 0 0% | $0 | 0 | 2 | |
| SARUBBI KIMBERLY | 0 0% | $0 | 0 | 1 | ||
| Krassan Mitchell | Chief Strategy Officer | 0 0% | $0 | 0 | 6 | |
| Rubric Capital Management LP | director | 0 0% | $0 | 4 | 1 | <0.0001% |
$2,074,565 | 1831 | -12.51% | $84.95M | |
$130,585,319 | 59 | 26.38% | $306.25M | |
$125,954,261 | 59 | -4.47% | $24.57M | |
TherapeuticsMD, Inc. (TXMD) | $30,221,759 | 51 | 0.50% | $21.07M |
$2,767,882 | 51 | 8.70% | $26.7M | |
$33,884,330 | 45 | 12.56% | $309.13M | |
$97,642,477 | 41 | -10.58% | $428.71M | |
$6,021,989 | 30 | -0.17% | $418.08M | |
$32,539,771 | 28 | 33.37% | $235.9M | |
$5,587,980 | 26 | -16.19% | $12.35M | |
$919,520 | 11 | 86.29% | $7.33M | |
$758,061 | 9 | 60.03% | $172.56M | |
$155,341 | 9 | -22.42% | $17.03M | |
$529,315 | 8 | 7.33% | $432.89M | |
$8,190,853 | 8 | -3.69% | $17.74M | |
$208,823 | 7 | -1.10% | $151.67M | |
$721,578 | 7 | -19.64% | $182.73M | |
$12,300,713 | 4 | 24.14% | $211.93M | |
$10,000 | 1 | -96.58% | $1.19M |
| Increased Positions | 11 | +21.15% | 134,413 | +4.07% |
| Decreased Positions | 13 | -25% | 53,312 | -1.61% |
| New Positions | 4 | New | 37,381 | New |
| Sold Out Positions | 6 | Sold Out | 25,610 | Sold Out |
| Total Postitions | 50 | -3.85% | 3M | +2.45% |
| Rubric Capital Management Lp | $1,967.00 | 9.94% | 1.19M | 0 | 0% | 2025-09-30 |
| Clearline Capital Lp | $1,048.00 | 5.29% | 635,222 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $622.00 | 3.14% | 376,828 | -2,173 | -0.57% | 2025-09-30 |
| Tejara Capital Ltd | $568.00 | 2.87% | 344,203 | -51 | -0.01% | 2025-09-30 |
| Adar1 Capital Management, Llc | $345.00 | 1.74% | 209,210 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $215.00 | 1.09% | 130,572 | -638 | -0.49% | 2025-09-30 |
| Blackrock, Inc. | $192.00 | 0.97% | 116,132 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $180.00 | 0.91% | 109,083 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $59.00 | 0.3% | 35,500 | +20,600 | +138.25% | 2025-09-30 |
| Citadel Advisors Llc | $57.00 | 0.29% | 34,273 | +34,273 | New | 2025-09-30 |